TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02253810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Medication administered intra-operatively to promote blood clotting.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study: NCT03199027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence Club
Description: Participants will be referred to an Adherence Club at 4 months post-ART initiation. Adherence club visits occur 2-4 monthly at a community hall near the Community Health Centre (CHC). At routine visits, which last 1-2 hours, community health workers provide health education, weigh patients, ask about symptoms and dispense pre-packed ART. Symptomatic patients are sent back to the ART clinic for clinician assessment. An assigned nurse takes blood tests annually at each club, and then returns on the subsequent visit to perform a clinical assessment and check the results. Patients requiring more follow-up or with high viral loads are referred back to the ART clinic at the CHC by the nurse.
Study: NCT01707056

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coffee with Milk
Description: Taking Synthroid with 12 ounces of black coffee and 2 ounces of 2% milk for a period of 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Black Tea
Description: Taking Synthroid with 12 ounces of black tea for a period of 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Taking Synthroid with water for a period of 6 weeks.
Study: NCT05606783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Follow-up Visits
Description: • Follow-up with patients once per week for six (6) weeks via scheduled 20-minute telehealth appointment with each patient via the HIPAA secure and compliant platform, VSee~o During this telehealth appointment, the study pharmacists will counsel the patients on their blood pressure readings for that week and provide lifestyle education focusing on patient-specific diet and exercise recommendations
Study: NCT03322228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music therapy is tailored to subject preference. Examples are active music-making, supportive listening, and includes opportunities for legacy building to decrease caregiver distress and promote self-care.
Study: NCT03037528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and lifestyle program
Description: Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and lifestyle program
Description: Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and lifestyle program
Description: Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and lifestyle program
Description: Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and lifestyle program
Description: Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and lifestyle program
Description: Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and lifestyle program
Description: Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and lifestyle program
Description: Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive affect informational materials
Description: Participants will be taught about positive affect skills, such as gratitude, positive reappraisal, and personal strengths.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive affect informational materials
Description: Participants will be taught about positive affect skills, such as gratitude, positive reappraisal, and personal strengths.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive affect informational materials
Description: Participants will be taught about positive affect skills, such as gratitude, positive reappraisal, and personal strengths.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive affect informational materials
Description: Participants will be taught about positive affect skills, such as gratitude, positive reappraisal, and personal strengths.
Study: NCT01647204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trained volunteer mealtime assistance
Description: trained volunteers helped inpatients at lunchtimes with dinner tray preparation, encouragement and feeding if required
Study: NCT04950452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Supervised exercise training
Study: NCT03142464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suspension of the IV fluids
Description: No IV fluids prescription, IV catheter filled with saline solution
Study: NCT03927209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: tablet
Study: NCT02096601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LD/CD SC solution
Description: Levodopa/carbidopa SC solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LD/CD SC solution
Description: Levodopa/carbidopa SC solution
Study: NCT05606783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys
Description: A pre- and post-survey will be given at the initial and final in-person appointments, respectively~• These surveys will collect basic patient demographics, knowledge of blood pressure, comfort with checking blood pressure at home, and previous experience working with a pharmacist

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Devices
Description: Smart Phones with Apple Health Software will be used to monitor blood pressure once a day, and results will be sent automatically to the patients EHR (Epic)~• The Omron 10 Series Wireless Upper Arm Blood Pressure Device will be given to the patient to monitor blood pressure at home daily
Study: NCT03544723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad-p53
Description: Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors. Immunotherapy. Gene Therapy.
Study: NCT01231893

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: olfactory mucosa ensheathing cell grafting, rehabilitation
Description: In this group patients are planned to underwent a biopsy of their own olfactory mucosa for isolation and culture of olfactory ensheathing cells and olfactory fibroblasts. The suspension of these cells will be next transplanted into the focus of spinal cord injury. Before and after surgery the patients will undergo an intense neurorehabilitation program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation
Description: In this group the patients will not undergo any surgical procedure. They will participate in the same rehabilitation protocol that is planned for the patients from the experimental group.
Study: NCT02096601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone
Description: Entacapone 200 mg oral tablet
Study: NCT03422614

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: Characterisation of cellular and functional phenotype in different PIDs

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: Characterisation of cellular and functional phenotype in different PIDs
Study: NCT01802021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astagalus-based Formula: Qingshu-Yiqi-Tang
Description: Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy.~maximal for 6 months
Study: NCT00137501

Intervention type: DRUG
Group type: OTHER
Intervention: Nifedipine
Description: Arm A:~Nifedipine 20 mg sublingual, repeated after 30 minutes if contractions do not decrease in intensity. Maintenance of 120-160 mgs of slow-release nifedipine daily for 48 hours.Once contractions cease, nifedipine will be maintained at 80-120 mg daily in divided doses up to 36 weeks.~Arm B:~Nifedipine 10 mg sublingual crushed, then 10 mg in 15 min, followed by 10 mg PO Q 15 mins PRN to a maximum of 40 mg in the first hour. Maintenance of 60-80 mgs of slow-release nifedipine daily for 48 hours. Once contractions cease, nifedipine will be maintained at 60 mg daily in divided doses up to 36 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Nifedipine
Description: Arm A:~Nifedipine 20 mg sublingual, repeated after 30 minutes if contractions do not decrease in intensity. Maintenance of 120-160 mgs of slow-release nifedipine daily for 48 hours.Once contractions cease, nifedipine will be maintained at 80-120 mg daily in divided doses up to 36 weeks.~Arm B:~Nifedipine 10 mg sublingual crushed, then 10 mg in 15 min, followed by 10 mg PO Q 15 mins PRN to a maximum of 40 mg in the first hour. Maintenance of 60-80 mgs of slow-release nifedipine daily for 48 hours. Once contractions cease, nifedipine will be maintained at 60 mg daily in divided doses up to 36 weeks.
Study: NCT02159313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat(Adempas,BAY63-2521)
Description: Single dose of a whole 2.5 mg riociguat tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat(Adempas,BAY63-2521)
Description: Single dose of a whole 2.5 mg riociguat tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat(Adempas,BAY63-2521)
Description: Single dose of a whole 2.5 mg riociguat tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat(Adempas,BAY63-2521)
Description: Single dose of a whole 2.5 mg riociguat tablet
Study: NCT01276041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab in combination with trastuzumab and paclitaxel
Description: The regimen will consist of paclitaxel (80 mg/m2) weekly + trastuzumab every 3 weeks (8 mg/kg loading dose → 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose → 420 mg), all given intravenously (IV). Patients may be given trastuzumab weekly in lieu of every 3 weeks (4 mg/kg loading dose → 2 mg/kg every 3 weeks). Patients will be on treatment until progression of disease.
Study: NCT02897024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
Study: NCT02286843

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 89Zr-trastuzumab

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 89Zr-pertuzumab
Study: NCT01397357

Intervention type: OTHER
Intervention: Cardiac magnetic resonance - CINE MRI stress test.
Description: Cardiac magnetic resonance - dipyridamole or dobutamine MRI stress test.
Study: NCT04844112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: automatic CT/MRI-US fusion system guided radiofrequency ablation
Description: automatic CT/MRI-US fusion system guided radiofrequency ablation
Study: NCT00631215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy: 1.3 atmospheres of pressure, 100%0xygen by face mask, for 60 minutes
Study: NCT03701893

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus PS11610
Description: 7 months and a half intervention study. A 6 months intervention period preceded by a period of sampling and analysis of vaginal, seminal and gland swabs of 6 weeks. During the 6 months of intervention the men participants will intake one capsule that contains 1\*10E9 colony forming unit (CFU) of Lactobacillus PS11610 and the women participating will intake two capsules of the same product (each 12 hours). If the couple stay pregnant during the intervention the man will end the product intake and the woman will reduce the dose to one capsule with 1\*10E9 CFU of Lactobacillus PS11610 per day during 12 additional weeks.
Study: NCT03754010

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planning
Description: Under local anesthesia, full-mouth SRP will be performed by a single investigator. Immediately after the SRP, HA gel or mouthrinse will perform according to the groups' procedure. In Group 1, the periodontal sulcus will be irrigated with saline solution after SRP.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planning
Description: Under local anesthesia, full-mouth SRP will be performed by a single investigator. Immediately after the SRP, HA gel or mouthrinse will perform according to the groups' procedure. In Group 1, the periodontal sulcus will be irrigated with saline solution after SRP.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planning
Description: Under local anesthesia, full-mouth SRP will be performed by a single investigator. Immediately after the SRP, HA gel or mouthrinse will perform according to the groups' procedure. In Group 1, the periodontal sulcus will be irrigated with saline solution after SRP.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planning
Description: Under local anesthesia, full-mouth SRP will be performed by a single investigator. Immediately after the SRP, HA gel or mouthrinse will perform according to the groups' procedure. In Group 1, the periodontal sulcus will be irrigated with saline solution after SRP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel (HA) and SRP
Description: In Group 2, after SRP will be performed and irrigated with saline the area was dried with a soft air and, then, a gel containing HA will be applied intrasulcular.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA mouthrinse and SRP
Description: In Group 3, HA hydrogel mouthrinse will be used as an irrigator after SRP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA mouthrinse+gel and SRP
Description: In Group 4, after SRP will be performed, the sulcus was irrigated with HA hydrogel mouthrinse and, then, intrasulculary HA gingival gel will be applied.
Study: NCT03423797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25% AgNO3 solution followed by 5% NaF
Description: Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF: 11.6mg (F-)/0.5ml (max dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25% AgNO3 solution followed by 5% NaF with fTCP
Description: Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF with fTCP: 11.6mg (F-)/0.5ml (max dose).
Study: NCT04109586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized nutritional therapy
Description: Dietitian led assessment and individual nutritional therapy during inpatient rehabilitation with follow-up the first year after injury
Study: NCT01486225

Intervention type: DEVICE
Group type: OTHER
Intervention: Innothera's brand Stockings
Description: 15 patients having used Innothera branded Stocking

Intervention type: OTHER
Group type: OTHER
Intervention: Stockings other than Innothera's brand
Description: 15 patients having used any other brand than Innothera's brand stockings
Study: NCT01791309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination panitumumab and vemurafenib
Description: Treatment will consist of panitumumab 6mg/kg IV every 14 days and vemurafenib 960mg orally twice daily. In patients who initially respond to treatment and later progress, a voluntary biopsy will be requested at the time of relapse to study mechanisms of acquired resistance. This biopsy should consist of at least one frozen core specimen. Every effort will be made to obtain this biopsy within 30 days of discontinuation of treatment and before the initiation of any new tumor-directed therapies.
Study: NCT00725920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: patients will receive the active drug. The starting dose was 25 mg/day, with weekly increments of 25 mg/day, according to clinical status. The maximum dose considered was 200 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control group
Description: initial dose 25 mg day, increments of 25 mg each 2 weeks. Up to 100 mg/day Those with no intolerance and no response dose could be up to 200 mg day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo control group
Description: initial dose 25 mg day, increments of 25 mg each 2 weeks. Up to 100 mg/day Those with no intolerance and no response dose could be up to 200 mg day
Study: NCT04215887

Intervention type: DEVICE
Intervention: Contactless Portable Respiratory rate Monitor
Description: Novel hand-held respiratory rate monitor

Intervention type: DEVICE
Intervention: Contactless Portable Respiratory rate Monitor
Description: Novel hand-held respiratory rate monitor

Intervention type: DEVICE
Intervention: Contactless Portable Respiratory rate Monitor
Description: Novel hand-held respiratory rate monitor

Intervention type: DEVICE
Intervention: Contactless Portable Respiratory rate Monitor
Description: Novel hand-held respiratory rate monitor

Intervention type: DEVICE
Intervention: Contactless Portable Respiratory rate Monitor
Description: Novel hand-held respiratory rate monitor
Study: NCT04245254

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Protien Powder
Description: Collegen Protein Powser
Study: NCT02244281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01687894

Intervention type: DRUG
Intervention: Vasopressins
Description: Vasopressins propofol vasopressins sevoflurane

Intervention type: DRUG
Intervention: Vasopressins
Description: Vasopressins propofol vasopressins sevoflurane

Intervention type: DRUG
Intervention: Placebo
Description: Placebo propofol \& placebo sevoflurane

Intervention type: DRUG
Intervention: Placebo
Description: Placebo propofol \& placebo sevoflurane
Study: NCT03037528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness informational materials
Description: Participants will be taught about mindfulness and mindful eating techniques.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness informational materials
Description: Participants will be taught about mindfulness and mindful eating techniques.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness informational materials
Description: Participants will be taught about mindfulness and mindful eating techniques.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness informational materials
Description: Participants will be taught about mindfulness and mindful eating techniques.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary tracking
Description: Participants will be asked to track their diet consistently.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary tracking
Description: Participants will be asked to track their diet consistently.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary tracking
Description: Participants will be asked to track their diet consistently.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary tracking
Description: Participants will be asked to track their diet consistently.
Study: NCT00605046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECT scan
Description: AV151-01: Evaluation of \[123I\] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
Study: NCT01467999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Guanfacine, 4mg given once daily
Study: NCT02787473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Pemetrexed 500mg/m2 IV on day 1 every 4 weeks for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin 25mg/m2 IV on day 1-3 every 4 weeks for 2 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiation therapy
Description: Chemoradiotherapy, radiation 60Gy with 2 cycles of pemetrexed+ carboplatin/cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel 60 mg/m2 IV on day 57 every 3 weeks for 2 cycles